BiotechTube

Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2)

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Autoimmune Inner Ear Disease

Conditions

Autoimmune Inner Ear Disease, Meniere's Disease

Trial Timeline

Jan 3, 2019 → Dec 31, 2025

NCT ID
NCT03587701

About Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2)

Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2) is a phase 2 stage product being developed by Swedish Orphan Biovitrum for Autoimmune Inner Ear Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03587701. Target conditions include Autoimmune Inner Ear Disease, Meniere's Disease.

What happened to similar drugs?

0 of 13 similar drugs in Autoimmune Inner Ear Disease were approved

Approved (0) Terminated (3) Active (10)
🔄SatralizumabChugai PharmaceuticalPhase 3
🔄Enteric-coated Mycophenolate SodiumNovartisPhase 3
🔄Ianalumab + PlaceboNovartisPhase 3
🔄rituximab (Mabthera®) + PlaceboRochePhase 3
🔄rilzabrutinib + placeboSanofiPhase 3
❌parsaclisinib + placeboIncytePhase 3
❌Intravenous Immunoglobulin + Placebos + Normal SalineGrifolsPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03587701Phase 2Recruiting

Competing Products

20 competing products in Autoimmune Inner Ear Disease

See all competitors
ProductCompanyStageHype Score
SatralizumabChugai PharmaceuticalPhase 3
47
SHR0302 quick release tablets + SHR0302 sustained-release tabletsJiangsu Hengrui MedicinePhase 1
29
HR19042 Capsule, Tarpeyo®, Budenofalk®Jiangsu Hengrui MedicinePhase 1
29
HR19042 CapsulesJiangsu Hengrui MedicinePhase 2
35
Enteric-coated Mycophenolate SodiumNovartisPhase 3
40
Ianalumab + PlaceboNovartisPhase 3
44
VAY736NovartisPhase 2/3
38
remibrutinibNovartisPhase 1
29
RO7049665RochePhase 2
27
rituximab (Mabthera®) + PlaceboRochePhase 3
40
NovoMix 30 + Tablet treatmentNovo NordiskPre-clinical
22
branebrutinib + abatacept + branebrutinib placeboBristol Myers SquibbPhase 2
35
BMS-986165Bristol Myers SquibbPhase 1
29
NivolumabBristol Myers SquibbPhase 1
21
Fludarabine + Cyclophosphamide + TocilizumabBristol Myers SquibbPhase 1
36
BMS-986165 + RosuvastatinBristol Myers SquibbPhase 1
29
SAR445088SanofiPhase 1
21
BIVV020SanofiPhase 1
29
rilzabrutinibSanofiPhase 2
39
rilzabrutinib + placeboSanofiPhase 3
47